On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array

...

Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently. Celera is a healthcare business focusing on the integration of genetic testing into routine clinical care through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Through this co-marketing agreement, Proven Diagnostics will provide selected diagnostic tools from BHL’s menu of proprietary cardiovascular tests and services which aims at optimizing cardiovascular treatment, these include BHL’s 4myheart cardiovascular disease management program as well.

Proven Diagnostics is a new clinical diagnostic laboratory service provided by Geisinger Health System that is designed to provide medical professionals access to a wide array of clinical laboratory services. These services include microbiology, biochemical and

...

On June 26, 2009, Genomic Health Inc (GHDX) reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended the usage of validated multigene assays, such as Oncotype DX, as an adjunct to standard measures in determining the benefits of chemotherapy for early-stage breast cancer patients.

We believe that these recommendations go a long way in expanding the scope of Oncotype DX further in breast cancer treatment in the European market.

As a reminder, Oncotype DX, backed by clinical evidence, has the ability to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit for early stage breast cancer patients. Since its launch in January 2004, Oncotype DX has been used in more than 100,000 patients in over 40 countries worldwide for breast cancer treatment planning. More than 90% of the U.S. insured lives are covered

...

Highlights include Celera Corporation (CRA) and Abbott Laboratories (ABT).Celera Corporation: 1Q09 financials improve; challenges ahead

Celera Corp. (CRA) recently reported first quarter 2009 financials.

Total revenue came in at $45.7 million for the first quarter of 2009 ended March 31, 2009, compared to $39.5 million in the prior year quarter. Total revenue was slightly ahead of our estimate of $43 million.

Revenue by segment for the first quarter 2009 was as follows:   

Lab services revenue was $28.5 million compared to $22.3 million in the prior-year quarter, primarily due to increased test volumes and the broad-scale launch of the blood-based KIF6 test in July 2008. Lab service revenue exceeded our estimate of $25 million for the quarter.     Products revenue was $10.4 million compared to $9.3 million in the prior-year quarter. Revenue for the ...